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Abstract
As proviral human immunodeﬁciency virus type 1 (HIV-1) DNA can replenish and revive viral infection upon activation, its detection
might offer signiﬁcant therapeutic information, complementing the input provided by plasma RNA determination in the follow-up of
infected individuals. A selected group of acutely infected subjects was studied to verify both total and 2-long terminal repeat (2-LTR)
DNA proviral load during the acute phase of infection and thereafter. Patients were divided in two sex- and age-matched groups: 19
naive individuals who did not receive antiretroviral therapy during the observation period and 20 subjects treated according to current
guidelines. Total and 2-LTR HIV-1 DNA proviral load, in addition to RNA viral load and CD4 cell count, were determined in peripheral
blood mononuclear cells (PBMC) at baseline, 6 and 12 months after the ﬁrst sampling. Total and 2-LTR HIV-1 DNA proviral load
exhibited no signiﬁcant variation at any time in the naive patients (total HIV-1 DNA ranging from 896 ± 731 to 715 ± 673 copies/
105 PBMC and 2-LTR HIV-1 DNA ranging from 94 ± 105 to 65 ± 44 copies/105 PBMC), whereas a signiﬁcant reduction in both total
HIV-1 DNA (ranging from 997 ± 676 to 262 ± 174 copies/105 PBMC) and 2-LTR HIV-1 DNA proviral load (ranging from 116 ± 55 to
26 ± 35 copies/105 PBMC) was detected in highly active antiretroviral therapy (HAART) patients, together with a CD4+ T cell count
increase and RNA load decrease. HAART negatively affects both the labile HIV burden and the integrated proviral DNA, at least in
the initial period of successful treatment, suggesting that quantiﬁcation of HIV-1 DNA proviral load may be an important parameter in
monitoring HIV infection.
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Introduction
Although highly active antiretroviral therapy (HAART) can
decrease virus load in plasma to undetectable levels, infection
cannot be eradicated due to the perpetuation of viral reser-
voirs [1,2] established early in the infection. Human immuno-
deﬁciency virus (HIV) is persistently stored in a stable form
in some speciﬁc cell lineages [2–5] and is protected from
biochemical decay.
The origin of viral rebound is still not completely eluci-
dated, but is tightly linked to the persistence and transcrip-
tional activation of HIV proviral DNA in cellular reservoirs
and anatomical compartments [6–11].
Some activated T cells physiologically revert to a resting
state due to the reduction or loss of key cellular factors
involved in HIV replication. Hence, HIV enters a latent cycle
that may be re-activated to a full replication cycle when the
resting memory cell is stimulated by speciﬁc antigens [1,5].
This process proceeds during chronic infection throughout
the lives of infected individuals, creating a complex archive of
wild-type and mutant viruses generated throughout active
viral replication [2,5,12].
All these observations suggest that the analysis of HIV
DNA proviral load, in addition to RNA viral load, could
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be considered a useful marker during the follow-up of
infected individuals, to evaluate reservoir status and the
antiretroviral efﬁcacy of new, more potent therapeutic
regimens.
Most studies have focused on total DNA proviral load
characterized by quantitative determination of the overall
HIV DNA pool [13–22]. The HIV DNA provirus is formed
by reverse transcription of viral RNA into double-stranded
linear DNA in the cytoplasm. The resulting linear DNA mol-
ecule is actively transported to the nucleus as a component
of the pre-integration complex, the immediate precursor for
the subsequent integration process. Proviral forms are stable
structures that remain indeﬁnitely in the host cell genome
and serve as templates for viral transcription [5]. Besides the
integrated forms, unintegrated forms such as episomal or
linear HIV DNA have been observed: episomal HIV DNA is
formed after completion of cDNA even though unintegrated
HIV-1 DNA may assume several monomeric and multimeric
forms. This full-length cDNA is transported to the nucleus,
where a proportion undergoes circularization to form epi-
somes containing one or two long terminal repeats (LTRs).
Several groups [23–29] have attempted to address the possi-
ble function, activity, and importance of unintegrated epi-
somal HIV DNA during the life cycle of retroviruses and the
course of retroviral-associated diseases. It has been shown
that the 2-LTR HIV DNA form might be considered a
molecular determinant of infectivity [25–29].
Despite a growing number of studies involving the quanti-
ﬁcation of HIV DNA in HAART-treated patients, few data
[14,28,30,31] have been published on HIV DNA in patients
before treatment or untreated during the initial phase of
infection.
In this report, we used quantitative analysis of episomal
2-LTR and total HIV DNA load to investigate the dynamics
of the HIV-1 DNA reservoir in naive or subsequently HA-
ART-treated patients with acute HIV-1 infection, to establish
the possible role of both integrated and 2-LTR DNA load in
the evaluation of HIV infection.
Materials and Methods
Blood samples
Blood samples collected from 39 acute HIV-1 seroconverters
were included in the study after informed consent was
obtained according to the Helsinki Declaration (1975) guide-
lines. Seroconverters were deﬁned as patients presenting
HIV enzyme immunoassay antibody results that evolved from
negative/equivocal to positive in closely consecutive samples.
The virological and immunological evaluation was per-
formed at the ﬁrst evidence of HIV-1 seropositivity [samples
collected within 6 months after the estimated seroconver-
sion (baseline sample: Time 1), 6 months later or 5 weeks
after the beginning of therapy (Time 2) and at the end of the
observation period (up to 12 months from baseline: Time
3)]. Intensive medical evaluation ruled out a history of drug
abuse and a sexual transmission route was established in all
HIV-1-infected subjects.
Patients were divided into two groups: untreated group
A comprised 19 HIV-1-naive patients who never received
TABLE 1. Antiretroviral treatment
[two nucleotide reverse
transcriptase inhibitors (NRTI) and
one non-nucleotide reverse
transcriptase inhibitors (NNRTI)] in
HIV-1 patients (group B)
Antiretroviral treatment
NRTI NNRTI
Patient N1 FTC+TDF EFV
Patient N2 FTC+TDF EFV
Patient N3 ABC+3TC NVP
Patient N4 3TC+TDF NVP
Patient N5 3TC+ABC EFV
Patient N6 AZT+3TC NVP
Patient N7 FTC+TDF EFV
Patient N8 AZT+3TC EFV
Patient N9 3TC+ABC NPV
Patient N10 FTC+TDF EFV
Patient N11 3TC+TDF EFV
Patient N12 AZT+3TC NVP
Patient N13 3TC+ABC EFV
Patient N14 3TC+TDF NVP
Patient N15 FTC+TDF EFV
Patient N16 ABC+3TC NVP
Patient N17 FTC+TDF EFV
Patient N18 AZT+3TC EFV
Patient N19 AZT+3TC EFV
Patient N20 3TC+ABC EFV
FTC, emtricitabine; TDF, tenofovir; ABC, abacavir; 3TC, lamivudine; AZT, zidovudine; EFV, efavirenz; NVP, nevira-
pine.
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any drug treatment during our follow-up period; treated
group B comprised 20 patients treated, about 6–7 months
after the evidence of acute infection, with a pharmacologi-
cal cocktail based on an association of two nucleotide
reverse transcriptase inhibitors and one non-nucleotide
reverse transcriptase inhibitor (Table 1). The two groups
were age- and sex-matched (13 men and six women vs.
15 men and ﬁve women, and 35 ± 9 vs. 38 ± 9.5 years,
respectively).
All patients were assessed for antibody detection and
avidity index at baseline and during follow-up. RNA, DNA
viral load and number of circulating CD4 lymphocytes were
determined at baseline and during follow-up.
Antibody detection
Antibodies were assessed using immunoenzymatic (Vironos-
tika, BioMerieux, the Netherlands) and immunoblot (Chiron
Co., Emerville, CA, USA) assays. A guanidine-based avidity
detection assay was used to analyse antibody avidity in all
sera as previously described [32–34].
CD4 cell count and RNA viral load determination
CD4+ lymphocyte count and plasma RNA viral load were
determined by ﬂow cytometry and by Quantiplex HIV-1 3.0
assay branched DNA kit (Siemens, East Walpole, MA, USA),
respectively. The lowest HIV-1 RNA detection limit was
determined to be 50 copies/mL.
Determination of HIV-1 proviral DNA in peripheral blood
mononuclear cells using SYBR Green real-time PCR
Peripheral blood mononuclear cells (PBMC) were isolated
from whole blood by Ficoll–HystoPaque gradient separation
(Amersham-Pharmacia,Uppsala, Sweden). Cell pellets (5 ·
105 PBMC) were stored at )80C. DNA was extracted and
puriﬁed by QIAmpDNA mini kit (Qiagen, Hilden, Germany)
and the DNA content was determined by spectrophotomet-
ric analysis at 260/280 nm. HIV-1 DNA proviral levels were
determined by SYBR Green-based real-time PCR assay as
previously described [2], using 300 ng of extracted DNA per
sample and SK431/SK462 gag primers as previously
described [2] to amplify a 142-bp gag fragment. Ampliﬁca-
tion, data acquisition and analysis were carried out using a
LightCycler instrument [LIGHTCYCLER 5.3.2 software (Roche,
Mannheim, Germany)]. For each run, a standard curve was
generated from a dilution series of DNA extracted from
8E5LAV lymphoblastoid cell line, which contains one inte-
grated copy of HIV-1 genome in each cell. All standard dilu-
tions and samples from patients were run in duplicate and
the average value of the copy number was employed to
quantify HIV-1 DNA copies in PBMC. Quantitative data
concerning the HIV-1 DNA load were expressed as number
of copies per 105 PBMC.
Determination of 2-LTR circles in PBMC using SYBR Green
real-time PCR
The PCR assay was performed in a ﬁnal volume of 20 lL,
using 2X Quantitect SYBR Green PCR Master Mix (Qiagen)
containing HotStarTaq DNA polymerase, 0.5 lM of each
oligonucleotide primer and 300 ng of DNA extracted from
clinical samples. The sequence of 2-LTR circle junction
primers is: 5¢-TAG ACC AGA TCT GAG CCT GGG A-3¢
and 5¢-GTA GTT CTG CCA ATC AGG GAA G-3¢. This set
of primers generates a 262-bp amplicon pair.
2-LTR gene ampliﬁcation was carried out as follows: one
cycle of 15 min at 95C (hot-start PCR) for initial activation,
followed by 50 cycles of 95C for 10 s, 60C for 30 s, 72C
for 30 s and 78C for 5 s.
A standard curve was generated from scalar dilution (from
105 to 10 copies) of plasmid DNA containing 2-LTR circle
HIV-1 DNA fragment (a kind gift of M. Capobianchi, Rome,
Italy). Results are expressed as 2-LTR circles copy number/
105 cells.
Phylogenetic analysis
HIV-1 subtypes were determined from HIV-1 pol gene
sequences [35]. Subtype assignment was determined by phy-
logenetic analysis using reference strains of known subtype
(Los Alamos database: http://www.hiv.lanl.gov). A neighbour-
joining method, using the Kimura 2-parameter distance esti-
mation method, was used to compare the sequences to pair-
wise distance matrices [36]. The consistency of the
phylogenetic clustering was tested using bootstrap analysis
with 100 replicates.
Statistical analysis
Student’s t-test, Mann–Whitney test and Pearson’s correla-
tion coefﬁcient were used to assess the association between
virological markers and other variables. Data were expressed
as means ± standard deviation (SD) (Table 2) or as med-
ian ± SD (Figs 1 and 2).
Results
Serological evaluation of acute infected HIV-1 patients
All samples derived from patients enrolled in the study were
examined for classical infection parameters at baseline and
subsequently monitored up to 12 months later.
The ﬁrst blood sample (baseline) was collected within
6 months of infection. Infection was established by a ﬁrst
642 Clinical Microbiology and Infection, Volume 16 Number 6, June 2010 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 640–646
serological positive test following a negative analysis
performed not more than 6 months earlier.
All the samples showed a low avidity index, conﬁrming a
recent infection, with a median OD value of 0.59 ± 0.15 at
Time 1 and a clear increasing value up to the end of the
observation period (0.76 ± 0.1 and 0.86 ± 0.1 at Time 2 and
Time 3, respectively). In parallel, Western blotting (WB)
showed a serum reactivity to at least one envelope protein
associated with two gag HIV-1 proteins in 36 out of 39
patients (classiﬁed as positive), and a serum reactivity to gp41
alone in three out of 39 subjects (classiﬁed as indeterminate
by WB analysis but positive for the presence of provirus by
qualitative PCR DNA) (data not shown). Western blots
were evaluated following the international criteria for HIV-1
serological interpretation (CDC, 1989).
CD4 cell count and RNA viral load and phylogenetic analysis
of HIV-1 coding sequences from plasma-derived virus
At baseline patients belonging to untreated group A (Table
2a) showed a mean value of 698 ± 228 CD4+ T cells/lL and
patients in treated group B (Table 2b) showed a mean value
of 413 ± 250 CD4+ T cells/lL (p 0.00).
A constant value (p 0.31) from baseline (T1) onwards was
observed in untreated patients (group A), whereas a rescue
of CD4+ cells by the end of the observation period (T3)
(p 0.08) was recorded in patients who received HAART
therapy (group B) during the course of our observation
period. HIV-1 RNA viral load analysis of group A showed
stable values (Table 2b) over time.
As expected, the HIV-1 RNA load of HAART-treated
patients (group B) showed a clear decrease at 5 weeks after
TABLE 2. CD4+ T cell count (mean value) (2a) and HIV-1 viral load (mean value) (2b) expressed as RNA copies/mL (mean
value) at baseline (T1) and afterwards (T2 and T3) in naive (group A) and treated (group B) patients
2a
CD4+ T cells/lL (mean value)
Time 1 Time 2 Time 3
Group A patients 698 ± 228 684 ± 231 630 ± 181
Group B patients 413 ± 250 466 ± 256 612 ± 439
2b
HIV-1 RNA viral load (mean value) copies/mL
Time 1 Time 2 Time 3
Group A patients 1 · 105 ± l · 105 5 · 104 ± 5 · 104 4 · 104 ± 3x104
Group B patients 2.3 · 105 ± l.7 · 105 1.2 · 103 ± 3.1 · 103 8.3 · 101 ± 1 · 102
FIG. 1. Proviral load total DNA at T1, T2 and T3 in patients
belonging to group A (untreated) and B (treated). Total DNA data
were expressed as median of log10 DNA copies/1 · 105 peripheral
blood mononuclear cells. Group A total DNA at baseline (T1): med-
ian 2.86 log10; at 6 months (T2): median 2.57 log10; at the end of
observation period (T3): median 2.72 log10. Group B total DNA at
baseline (T1): median 2.72 log10; at 6 months (T2): median 2.61
log10; at the end of observation period (T3): median 2.24 log10.
FIG. 2. 2-Long terminal repeat (2-LTR) DNA at T1, T2 and T3 in
patients belonging to group A (untreated) and B (treated). 2-LTR
data were expressed as median of log10 2-LTR copies/1 · 105
peripheral blood mononuclear cells. Group A 2-LTR HIV DNA at
baseline (T1): median 1.47 log10; at 6 months (T2): median 1.0 log10;
at the end of observation period (T3): median 1.75 log10. Group B
2-LTR HIV DNA at baseline (T1): median 1.74 log10; at 6 months
(T2): median 1.40 log10; at the end of observation period (T3):
median 1.0 log10.
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the start of therapy (T2; p <0.05) (Table 2b) and a further
reduction was detectable at 12 months [from 2.3 · 105 HIV
RNA copies/mL to very low levels (T3; p <0.05)], concurrent
with the increase in CD4+ T cell count already described
above.
Phylogenetic analysis of HIV-1 pol gene (RT and PR)
sequences ampliﬁed directly from plasma revealed that all
patients were infected with subtype B virus (data not shown)
Total HIV-1 DNA proviral and HIV-1 2-LTR DNA proviral
load
Total HIV-1 DNA proviral load did not exhibit any apprecia-
ble difference (Fig. 1) from T1 to T3 (median 2.86 log10 (T1);
2.57 log10 (T2); and 2.72 log10 (T3), p >0.1) in naive patients
(group A). On the other hand, PBMC total HIV-1 DNA pro-
viral load in HAART-treated patients (group B) decreased
signiﬁcantly between T1 and T3 (median 2.72 log10 vs. 2.24
log10; p 0.00).
In parallel, assaying the 2-LTR DNA episomal form in
naive patients gave median values of 1.47 log10, 1.0 log10 and
1.75 log10 at T1, T2 and T3, respectively, (T1 = median) and
a progressive and signiﬁcant decrease between T1 and T3
(median 1.74 log10 vs. 1.00 log10; p 0.02) over time in
HAART-treated patients (Fig. 2). Interestingly, 13 out of 20
subjects belonging to group B showed undetectable amounts
of HIV-1 2-LTR episomal DNA at T3 (the sensitivity limit of
the technique is 10 copies/1 · 105 PBMC). PBMC HIV-1
2-LTR DNA load showed a signiﬁcant correlation with RNA
load (p < 0.001) and only an inverse trend with CD4 cell
count (p < 0.009).
Although both treated and untreated patients showed a
decrease in 2-LTR DNA between T1 and T2, the quantiﬁca-
tion of the 2-LTR circular HIV DNA showed that treated
patients showed a lower level of 2-LTR DNA content and a
net decrease of >0.5 log10 (1.74 log10 vs. 1.00 log10) at the
end of our observation period.
Discussion
HIV-1 proviral DNA load is an important marker for moni-
toring the HIV-1 reservoir. Low levels of ongoing, persistent
HIV replication may contribute to the longevity of the latent
viral reservoir by continually fuelling new rounds of infection
in resting CD4+ T cells. The quantiﬁcation of HIV DNA in
peripheral blood cells, in addition to RNA viral load in
patients’ plasma, may be extremely important for disease
monitoring, especially in HAART-treated patients [23,27,
37–39], when RNA viral load is undetectable by current
techniques [25,30,40,41].
This report studied total and 2-LTR circular HIV-1 DNA
proviral load, by SYBR Green-based real-time PCR, a useful
and reliable approach for determining genome regions with a
high mutation rate [41–43]. Standardized methods for the
measurement of the two most signiﬁcant forms of proviral
DNA, total and non-integrated, are currently lacking, despite
the widespread use of molecular biology techniques.
In line with other reports [18,44,48], our molecular
approach, performed in acutely infected patients with 1 year
of follow-up, demonstrated that HAART-treated individuals
show a signiﬁcant decrease in both total and 2-LTR circular
HIV-1 DNA proviral load in PBMC compared with naive
patients (coupled with a signiﬁcant increase in CD4 cell
count and a drop in viral replication). These ﬁndings conﬁrm
that HIV-1 reservoir decay correlates with therapeutic effec-
tiveness [18,49–51].
Persistence of HIV-1 reservoirs might result in viral
rebound when therapy is interrupted or discontinued
[16,21,37]. It is reasonable to assume that decreasing DNA
loads reﬂect at least partial exhaustion of HIV-1 reservoirs.
Interestingly, when we focused on the 2-LTR HIV-1
DNA load, which is considered to be a molecular deter-
minant of infectivity, we also observed a signiﬁcant and
longitudinal decrease in the HAART group compared with
the group of naive subjects. This suggests a direct role of
therapy, starting very early after the estimated serocon-
version. We were able to determine low levels of detect-
able 2-LTR HIV-1 DNA load in 13 out 20 group B
subjects (65% of the population examined), in agreement
with other reports [23,29].
Previous research [25,27] has demonstrated that at least
50% of individuals given long-standing treatment, and having
undetectable viral loads for sustained periods of time, had
detectable 2-LTR circular DNA, showing that labile replica-
tion intermediates are present in a substantial proportion of
HIV-1-infected individuals.
Since our study focused on a small group of patients, with
follow-up to 12 months after certiﬁcation of acute infection,
the few patients with undetectable 2-LTR amounts could be
explained by a transitory decrease due to a partial but
consistent pause in viral replication.
In fact, we found a decrease in both total and 2-LTR
DNA in HAART-treated patients at 5 weeks after the begin-
ning of therapy, which was associated with an increased CD4
cell count.
The persistence of small amounts of 2-LTR HIV-1 DNA
in PBMC from some patients demonstrates that a small rate
of replication is retained even when HAART is substantially
effective. These observations conﬁrm that HAART could
not eradicate the infection because HIV is able to replicate
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even in the presence of effective therapy. Plasma-based viral
RNA assays may fail to demonstrate the full extent of viral
activity.
By contrast, a trend of increasing 2-LTR DNA load in
naive patients emphasizes that viral replication is constantly
active in this group. The absence of therapy can lead to con-
tinuous viral replication with the further accumulation of
proviral load and also 2-LTR labile forms.
There have been contrasting reports on the implications
of DNA proviral content in HIV-1 patients [30,43,45–47,51–
53]. However, our data, obtained for closely controlled
patients, emphasize the importance of DNA proviral quantiﬁ-
cation in HIV-1 patients. Viral persistence provides a mecha-
nism for life-long persistence of replication-competent HIV-1,
rendering hopes of virus eradication with current antiretrovi-
ral regimens unlikely.
Although RNA viral load provides important information
on viral replication, HIV-1 DNA proviral load can be consid-
ered an additional marker to provide crucial information.
Only a thorough evaluation of both virological markers will
fully characterize the course of HIV-1 infection and provide a
more complete laboratory-based assessment of disease pro-
gression. In conclusion, the availability of a new standardized
assay to determine DNA proviral load will be important in
assessing the true extent of virological suppression and in
verifying the efﬁcacy of new immune-based therapies aimed
at purging HIV-1 DNA reservoirs.
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